Dallas, TX: ReportsandReports announce it will carry Eisai Co. Ltd: PharmaVitae Profile Market Research Report in its Store. Browse complete Eisai Co. Ltd: PharmaVitae Profile Report Introduction This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase Table Of Contents CHAPTER 1 ABOUT THIS PROFILE 2 Executive summary 2 Quarterly news update 2 Company introduction 2 Company sales 2 Company financials 2 Key products and competitors 3 Data sourcing 3 Sales data 3 Analyst consensus 3 CHAPTER 2 EXECUTIVE SUMMARY 4 Key findings 4 Prescription pharmaceutical sales performance, 2001-13 5 Financial performance, 2001-13 6 Eisai: PharmaVitae forecasts at a glance 7 Strategic insight 8 1) 2001-07: Impressive Rx revenue growth 8 2) 2007-10: M&A sustains Rx revenue 9 3) 2010-13: Life after Aricept and AcipHex? 10 Aricept and AcipHex/Pariet face generic competition over 2010-13 10 Launch portfolio unable to offset expiry declines 10 Further M&A on the horizon? 11 Operating margin remains robust despite revenue decline 11 SWOT analysis 12 Strengths 12 Weaknesses 13 Opportunities 13 Threats 15 CHAPTER 3 QUARTERLY NEWS UPDATE 20 Product developments 20 Deals and alliances 21 Product deals 21 Technology deals 22 M&A activity 23 Company announcements 23 Future product milestones 24 CHAPTER 4 COMPANY INTRODUCTION 25 Key findings 25 Background 26 Key corporate developments 26 M&A history 27 Merger of Sakuragaoka Research Laboratory and Nihon Eisai 27 Acquisition of Morphotek 27 Acquisition of Sanko Junyaku 27 Acquisition of MGI Pharma 28 Current corporate structure 29 Pharmaceuticals business unit structure 30 Pharmaceuticals business unit structure 30 Prescription pharmaceuticals (Rx) 30 Diagnostics 31 Consumer healthcare 31 CHAPTER 5 COMPANY SALES 32 Key findings 32 Prescription pharmaceutical sales and growth rate analysis, 2001-13 33 Product analysis 35 Product analysis, 2001-07 35 Product analysis, 2007-13 39 Therapy area analysis 43 Therapy area analysis, 2001-07 44 Therapy area analysis, 2007-13 46 Therapy area focus, 2001-13 48 Geographic analysis 49 Geographic analysis, 2001-07 50 Geographic analysis, 2007-13 51 Geographic focus, 2001-13 55 Launch/core/expiry analysis 56 Explanation of launch/core/expiry analysis 56 Launch analysis, 2007-13 57 Core analysis, 2007-13 59 Expiry analysis, 2007-13 60 Launch/core/expiry configuration, 2007-13 62 Molecule type analysis 63 Molecule type analysis, 2001-07 64 Molecule type analysis, 2007-13 65 Externalization analysis 67 Externalization analysis, 2001-07 68 Externalization analysis, 2007-13 70 CHAPTER 6 COMPANY FINANCIALS 73 Key findings 73 Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 74 Financial statements, 2001-07 76 Profit and loss account, 2001-07 76 Balance sheet, 2001-07 78 Operating costs and profit analysis 80 Operating costs and profit analysis, 2001-07 81 Operating cost ratio and profit margin analysis, 2001-07 83 Operating cost ratio and profit margin analysis, 2007-13 84 Operating costs and profit analysis, 2007-13 86 Return on capital employed analysis 88 Capital employed analysis, 2001-07 89 Return on capital employed analysis, 2001-07 91 Market capitalization analysis 93 Market capitalization analysis, 2001-07 93 Total shareholder returns analysis, 2001-07 94 CHAPTER 7 KEY PRODUCTS AND COMPETITORS 95 Key findings 95 Overview 96 Central nervous system 97 Aricept 97 Overview 97 Sales forecast 98 Methycobal 100 Overview 100 Sales forecast 101 Lusedra 102 Overview 102 Sales forecast 103 Inovelon/Banzel 104 Overview 104 Sales forecast 105 Gastroenterology 107 AcipHex/Pariet 107 Overview 107 Sales forecast 108 Selbex 111 Overview 111 Sales forecast 112 Oncology 113 Aloxi 113 Overview 113 Sales forecast 114 Dacogen 116 Overview 116 Sales forecast 117 E7389 120 Overview 120 Sales forecast 121 Gliadel 123 Overview 123 Sales forecast 124 Infectious disease 125 E5564 125 Overview 125 Sales forecast 126 Immunology and inflammation 128 Humira 128 Overview 128 Sales forecast 129 CHAPTER 8 APPENDIX 130 R&D pipeline 130 Indication broadening pipeline 131 References 132 Abbreviations 133 Exchange rates 134 Browse complete Eisai Co. Ltd: PharmaVitae Profile Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports RSS Browse all Latest Report Related Reports: Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Daiichi Sankyo Co., Ltd: PharmaVitae Profile Bristol-Myers Squibb Co.: PharmaVitae Profile About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Posted by
Unknown
on